Quick Answer
RenovoRx, Inc. reported Research And Development Expense of $6.27 million for the year ending 2025.
- RenovoRx, Inc. showed an increase of +4.0% in Research And Development Expense from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $727.0 thousand | Q1 2021: $635.0 thousand | Q2 2021: $536.0 thousand | Q3 2021: $767.0 thousand | Q1 2022: $1.29 million | Q2 2022: $1.39 million | Q3 2022: $846.0 thousand | Q1 2023: $1.34 million | Q2 2023: $1.93 million | Q3 2023: $1.63 million | Q1 2024: $1.26 million | Q2 2024: $1.54 million | Q3 2024: $1.65 million | Q1 2025: $1.64 million | Q2 2025: $1.43 million | Q3 2025: $1.69 million.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Research And Development Expense has grown by 162.7%.
- Historical annual values: Fiscal year 2025: $6.27 million | Fiscal year 2024: $6.03 million | Fiscal year 2023: $5.67 million | Fiscal year 2022: $4.30 million | Fiscal year 2021: $3.04 million | Fiscal year 2020: $2.39 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: